New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;PFE From The Last 14 Days
Check below for free stories on GSK;PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 21, 2014
06:47 EDTPFEAstraZeneca volatility elevated, said to have been approached by Pfizer – report
AstraZeneca (AZN) implied volatility is expected is to move on Pfizer (PFE) is said to have approached to propose a $101B takeover, says the Sunday Times. Overall option implied volatility of 20 is above its 26-week average of 18 according to Track Data, suggesting large price movement.
06:40 EDTPFEPfizer volatility flat said to be considering bid for AstraZeneca – report
Subscribe for More Information
April 20, 2014
20:37 EDTPFEPfizer said to be considering GBP60B bid for AstraZeneca, Sunday Times says
Drug giant Pfizer (PFE) is said to have approached AstraZeneca (AZN) to propose a GBP60B takeover of the U.K company, says the Sunday Times. Informal discussions have recently taken place, say sources, but AstraZeneca is believed to be resisting Pfizer’s approach, added the Sunday Times. Reference Link
16:45 EDTPFEBiogen hemophilia drug Alprolix priced similar to older treatments, Reuters says
Subscribe for More Information
April 17, 2014
15:55 EDTGSKGlaxoSmithKline, Genmab get FDA approval for Arzerra use
GlaxoSmithKline (GSK) and Genmab (GNMSF) announced that the U.S. FDA has approved a Supplemental Biologic License Application for the use of Arzerra, a CD20-directed monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia for whom fludarabine-based therapy is considered inappropriate. The FDA approval of the first-line indication is based on results from a Phase III study which demonstrated statistically significant improvement in median progression-free survival in patients who received the combination of ofatumumab and chlorambucil compared to patients who received chlorambucil alone.
15:03 EDTGSKFDA grants wider approval for Glaxo's Arzerra in treatment of CLL
Subscribe for More Information
11:43 EDTGSKGlaxoSmithKline announces Canadian approval for Incruse Ellipta
GlaxoSmithKline announced that Incruse Ellipta has received market authorization in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, or COPD, including chronic bronchitis and emphysema. This is the first market authorization granted for this product anywhere in the world, the company noted.
08:38 EDTPFETeva settles patent ligitigation with Pfizer on Celebrex
Teva (TEVA) announced that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer (PFE) related to Teva’s generic version of Celebrex 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December 2014 or earlier under certain circumstances. Teva has received tentative approval from the U.S. Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100, 200 and 400 mg capsules. Sales of Celebrex were $2.2B in the U.S. according to IMS data as of December, 2013.
07:20 EDTGSKGlaxoSmithKline opens internal probe of bribery allegations, WSJ says
Subscribe for More Information
April 15, 2014
14:29 EDTGSKGlaxoSmithKline confirms FDA approval for Tanzeum
Subscribe for More Information
10:14 EDTGSKFDA approves Tanzeum to treat type 2 diabetes
The Food and Drug Administration approved Tanzeum subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. Tanzeum has a Boxed Warning to warn that tumors of the thyroid gland have been observed in rodent studies with some GLP-1 receptor agonists, but that it is unknown whether Tanzeum causes thyroid C-cell tumors, including a type of thyroid cancer called medullary thyroid carcinoma, in humans. Tanzeum should not be used in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2. The FDA approved Tanzeum with a Risk Evaluation and Mitigation Strategy, which consists of a communication plan to inform health care providers about the serious risks associated with Tanzeum. Tanzeum is manufactured by GlaxoSmithKline.
08:23 EDTGSKLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:06 EDTGSKProsonix, Mylan enter licensing deal for generic version of Flixotide, Flovent
Subscribe for More Information
08:04 EDTPFEWuXi PharmaTech names Steve Yang as COO and Executive VP
Subscribe for More Information
06:32 EDTGSK, PFEPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
09:05 EDTPFEGlycoMimetics presents GMI-1070 data
Subscribe for More Information
06:40 EDTGSKGlaxoSmithKline paid bribes to Polish doctors to promote Seretide, BBC says
Subscribe for More Information
April 11, 2014
07:19 EDTPFEAcura Pharma to host conference call
Subscribe for More Information
April 10, 2014
11:42 EDTGSKReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
06:17 EDTPFEAcura Pharma announces return of product rights from Pfizer
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use